Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model

article

Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/CIRCHEARTFAILURE.113.000539
P698PubMed publication ID24014826

P50authorAdelino F Leite-MoreiraQ37840717
André P. LourençoQ42441146
Inês Falcão-PiresQ52699695
Arantxa GonzalezQ56192180
Sara LeiteQ57395511
Dulce FontouraQ84273934
Carsten TschöpeQ90667359
P2093author name stringNazha Hamdani
Wolfgang A Linke
Walter J Paulus
Javier Díez
Begoña López
Peter Moritz Becher
Coen A Ottenheijm
Constantijn Franssen
Luisa Plettig
P433issue6
P921main subjectheart failureQ181754
ejection fractionQ641303
Heart failure with preserved ejection fractionQ3799239
P304page(s)1239-1249
P577publication date2013-09-06
P1433published inCirculation: Heart FailureQ2865806
P1476titleMyocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model
P478volume6

Reverse relations

cites work (P2860)
Q39310989A change of heart: oxidative stress in governing muscle function?
Q95295045A directed network analysis of the cardiome identifies molecular pathways contributing to the development of HFpEF
Q36114343A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II.
Q52919323A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction.
Q50865900A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.
Q90122980Adenosine Kinase Inhibition Augments Conducted Vasodilation and Prevents Left Ventricle Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction
Q33565707Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction
Q47648074Afterload-induced diastolic dysfunction contributes to high filling pressures in experimental heart failure with preserved ejection fraction.
Q37716248Age-dependent diastolic heart failure in an in vivo Drosophila model.
Q93269906Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction
Q90652972Alterations in Titin Properties and Myocardial Fibrosis Correlate With Clinical Phenotypes in Hemodynamic Subgroups of Severe Aortic Stenosis
Q47338830An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology
Q26764971Animal models of heart failure with preserved ejection fraction
Q39137992Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5.
Q94570857Both male and female obese ZSF1 rats develop cardiac dysfunction in obesity-induced heart failure with preserved ejection fraction
Q51545876Can Nitrite AMPk Up Sirt-ainty to Treat Heart Failure With Preserved Ejection Fraction?
Q38542448Cardiac Physiology of Aging: Extracellular Considerations.
Q38790312Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib.
Q38970479Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.
Q39106973Cardiovascular consequences of metabolic syndrome.
Q92813722Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
Q49385586Cellular mechanisms of metabolic syndrome-related atrial decompensation in a rat model of HFpEF.
Q98237619Cellular, mitochondrial and molecular alterations associate with early left ventricular diastolic dysfunction in a porcine model of diabetic metabolic derangement
Q64098202Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload
Q35875059Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
Q64239235Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population
Q38427211Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
Q26799594Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy
Q55182135Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction.
Q91027944Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model
Q90103714Disturbed cardiac mitochondrial and cytosolic calcium handling in a metabolic risk-related rat model of heart failure with preserved ejection fraction
Q36503059Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction
Q47722872Echocardiography and invasive hemodynamics during stress testing for diagnosis of heart failure with preserved ejection fraction: an experimental study.
Q35155257Emerging importance of oxidative stress in regulating striated muscle elasticity
Q89763523Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
Q53641091Excessive degradation of adenine nucleotides by up-regulated AMP deaminase underlies afterload-induced diastolic dysfunction in the type 2 diabetic heart.
Q47105925Exercise Training Reveals Inflexibility of the Diaphragm in an Animal Model of Patients With Obesity-Driven Heart Failure With a Preserved Ejection Fraction
Q38760688Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction
Q53241855From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress.
Q64890054Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology.
Q27000263Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies
Q48247164Human heart failure with preserved ejection versus feline cardiomyopathy: what can we learn from both veterinary and human medicine?
Q50099011Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction
Q37719325Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction.
Q41011024In vitro model to study the effects of matrix stiffening on Ca2+ handling and myofilament function in isolated adult rat cardiomyocytes.
Q34995889Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodeling
Q55000702Increased passive stiffness promotes diastolic dysfunction despite improved Ca2+ handling during left ventricular concentric hypertrophy.
Q38664204Inflammation - Cause or Consequence of Heart Failure or Both?
Q90482761Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction
Q38591546Intercellular communication lessons in heart failure
Q26765931Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?
Q52859813Latent ischaemia as a trigger for a circulus vitiosus of inflammation, fibrosis, and stiffness in HFPEF.
Q92330667Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction
Q43067579Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it's not one thing it's another
Q87789836Metabolic Syndrome Is Associated With Impaired Diastolic Function Independently of MRI-Derived Myocardial Extracellular Volume: The MESA Study
Q57045915Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus
Q49203906Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition".
Q26800076Myocardial hypertrophy and its role in heart failure with preserved ejection fraction
Q38780883Myocardial reverse remodeling: how far can we rewind?
Q35328760Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin
Q38246170New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction
Q51041886Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.
Q37468729Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism.
Q99555719Oxidative Stress and Inflammatory Modulation of Ca2+ Handling in Metabolic HFpEF-Related Left Atrial Cardiomyopathy
Q54750527Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.
Q47168770Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance
Q40318979Post-weaning high-fat diet accelerates kidney injury, but not hypertension programmed by maternal diabetes
Q93120821Posttranslational modifications of titin from cardiac muscle: how, where, and what for?
Q37696624Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
Q38670275Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials
Q48223158Protein phosphatase 5 regulates titin phosphorylation and function at a sarcomere-associated mechanosensor complex in cardiomyocytes.
Q48261592Radiation-induced HFpEF model as a potential tool for the exploration of novel therapeutic targets.
Q39626663Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants
Q53127213Renin overexpression leads to increased titin-based stiffness contributing to diastolic dysfunction in hypertensive mRen2 rats.
Q37116376Right Ventricular Myocardial Stiffness in Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis and Myofibril Stiffness.
Q46980824Right ventricular end-diastolic stiffness heralds right ventricular failure in monocrotaline-induced pulmonary hypertension.
Q36614556SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
Q47638072Spectral transfer function analysis of respiratory hemodynamic fluctuations predicts end-diastolic stiffness in preserved ejection fraction heart failure
Q52568928Stretch your heart-but not too far: The role of titin mutations in dilated cardiomyopathy.
Q39310690Tampering with springs: phosphorylation of titin affecting the mechanical function of cardiomyocytes
Q33863759Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.
Q38815425The Type 2 Diabetic Heart: Its Role in Exercise Intolerance and the Challenge to Find Effective Exercise Interventions
Q99710955The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model
Q90039918The role of fibroblast - Cardiomyocyte interaction for atrial dysfunction in HFpEF and hypertensive heart disease
Q26765101The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction

Search more.